Recent Company News

• 12:32 AM ET Aug 31, 2026
  

  Sumitomo Pharma trading higher; selected as one of five constituents of ESG investment index used by Japan GPIF (¥1544.5000, +59.5)

• 10:54 PM ET Aug 19, 2026
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 07:40 PM ET Aug 12, 2026
  

  Sumitomo Pharma America doses first patient in phase 1/2a study of DSP3077 for retinitis pigmentosa (¥1350.0000, 0)

• 01:33 AM ET Aug 04, 2026
  

  Sumitomo Pharma responds to Gotham City Research's 3-Aug shortseller report: company has found no evidence to substantiate allegations of misstatements or inappropriate accounting practices (¥1245.5000, -25)

• 11:09 PM ET Aug 03, 2026
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (42 total)

• 02:41 AM ET Jul 31, 2026
  

  Sumitomo Pharma reports Q1 net income attributable ¥17.00B, +52% vs year-ago ¥11.21B (¥1248.0000, 0)

• 07:08 PM ET Jul 21, 2026
  

  President Trump states tariff on generic drugs will stay at 0% for 2 years then rise to 100% - Truth Social

• 02:24 PM ET Jul 19, 2026
  

  FDA grants orphan drug designation to enzomenib (DSP-5336) for ALL (¥1261.0000, 0)

• 06:46 PM ET Jul 12, 2026
  

  Sumitomo Pharma upgraded to neutral from sell at Citi (¥1400.0000, 0)

• 01:35 AM ET Jun 19, 2026
  

  Sumitomo Pharma, Novo Nordisk Pharma receive Japan MHLW additional indication approval for wegovy subcutaneous injection (¥1453.0000, -72)